J&J/Inverness
This article was originally published in The Gray Sheet
Executive Summary
Proposed $1.3 bil. acquisition of Inverness Medical's diabetes care business by J&J, first announced May 9, is formalized in a definitive agreement May 23 (1"The Gray Sheet" May 14, 2001, p. 12). Anticipated to close by October, the deal remains subject to approval by shareholders and the Securities and Exchange Commission